These tumors also appear to be responsive to platinum-based chemotherapy [22], consistent with what has been shown for breast and ovarian cancer diagnosed in women who carry a germline pathogenic variant in BRCA1 and BRCA2. The identification of a germline pathogenic variant also provides information that is highly relevant to relatives, both men and women, as cascade testing can inform risk management strategies for family members. The gene discussed is BRCA1; the disease is ovarian cancer.